A $36 Stock With an "A" Rating

Its efforts to stop the virus have attracted attention...‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

SPONSORED Bill O'Reilly Did What?!? Bill O'Reilly is no stranger to controversy. The mainstream media LOVES bashing him. And they might just have a field day with this. Because Bill is releasing his most controversial project yet. See what it's all about right here. Editor's Note: Below, Chief Income Strategist Marc Lichtenfeld covers a stock that has attracted a lot of attention for its COVID-19 efforts. The pandemic has renewed investor interest in the biotech sector - and today's Rx for a healthy retirement no doubt involves investing in these innovative companies. That's why Marc wants to make it easy for you to learn more... He's offering a second year of his biotech research service, Lightning Trend Trader, for FREE to anyone who signs up today. So if you want to go beyond the biggest names in the sector and find tomorrow's winners... Click here to learn how you can join him. - Mable Buchanan, Managing Editor SAFETY NET Does Pfizer's COVID-19 Vaccine Secure Its Dividend? Marc Lichtenfeld, Chief Income Strategist, The Oxford Club Even before the COVID-19 pandemic hit, Pfizer (NYSE: PFE) investors were likely drawn to the stock's solid dividend and history of annual payout increases. Today, Pfizer yields 4.3% and has raised its dividend every year for 11 years. Can it continue to do so? And will its COVID-19 vaccine help ensure that the dividend is paid and raised? The drug giant saw declines in free cash flow starting in 2018, and only now is free cash flow expected to return to 2017 levels. Pfizer's payout ratio is very much under control. In 2020, the company paid out 69% of its free cash flow to shareholders in dividends. Because free cash flow is forecast to rise to $14.8 billion this year, the company is projected to pay out just 59% of its free cash flow in dividends. Generally speaking, a payout ratio below 75% of free cash flow is comfortable. SPONSORED Are You Ready for Stockflation? This unstoppable force is going to shake the market... Is your retirement portfolio prepared? Get Ready Now - See How COVID-19's Impact In 2020, Pfizer generated $42 billion in sales. This year, that number is expected to shoot higher to $62 billion. Of that $20 billion increase, $15 billion will come from the company's COVID-19 vaccine. The following year, that figure is forecast to drop to $4 billion. Then, it'll decline to $1 billion in 2023. So this year, the vaccine will have a profound effect on Pfizer's financials, though it will have a lesser impact the following years. But Pfizer had no problem affording its dividend even before this windfall from the vaccine. Regardless of what happens with this particular vaccine going forward, Pfizer should have no problem paying and raising its dividend in the near and intermediate future. Considering the company's solid payout ratio, rising cash flow and decadelong history of raising its payout to shareholders, Pfizer's dividend is safe regardless of the extra revenue from the vaccine. Dividend Safety Rating: A If you have a stock whose dividend safety you'd like me to analyze, leave the ticker in the comments section. Good investing, Marc P.S. Pfizer has a solid yield... but it's not my favorite healthcare stock right now. In fact, I've got my eye on a big emerging trend that's set to change the future of medicine. I want you to have the chance to profit from it. Click here and join me in Lightning Trend Trader, and I'll show you how. Leave a Comment TYPE A COMPANY'S NAME BELOW   MORE FROM WEALTHY RETIREMENT Why Equally Weighted Index Funds Outperform Why Phase 2 Trials Are Important to Investors (and Why I'm Enrolled in One) Is There Still Upside for the Biotech Sector? Facebook Twitter Email Share SPONSORED HUGE Profits, No Matter WHAT Direction a Stock Moves!? See how you could be the next to grab HUGE profits... Regardless of which way a stock moves. Up? You can win. Down? YOU CAN WIN! Click here now for the urgent details. You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2021 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 1.800.589.3430 | International: +1.443.353.4334 | Fax: 1.410.329.1923 Oxfordclub.com The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.